Cadila Healthcare's formulation manufacturing plant gets USFDA approval

Zydus group - Cadila Healthcare’s formulation manufacturing plant at Baddi, Himachal Pradesh has been approved by USFDA. With the approval in place the plant which currently caters to the domestic and emerging market requirements will commence supplies to the US market.

The USFDA approval for the Baddi plant enabled the company to open up an additional resource to cater to the growing needs of its US business. The ultra modern Baddi plant was commissioned in 2007 and manufactures oral solid dosage forms which include hard gelatin capsules and tablets.

Cadila Healthcare focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.